Evidence map›Paper›PMID 41706296›Full record

ArticleMolecular diversity2026

Discovery of 5-fluoro-aminopyrimidine derivatives as dual BTK/FLT3 inhibitors for the treatment of rheumatoid arthritis.

Fansheng Ran, Yifan Ma, Tiantian Sun, Liujie Ji, Qinyan Cai, Yanan Zhang, Yong Ling, Chunlin Zhuang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fansheng RanSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, China.
Yifan MaSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, China.
Tiantian SunSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, China.
Liujie JiSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, China.
Qinyan CaiSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, China.
Yanan ZhangSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, China.
Yong LingSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, China. Lyyy111@sina.com.
Chunlin ZhuangSchool of Pharmacy, Second Military Medical University, Shanghai, 200433, China. zclnathan@163.com.

Funding

China Postdoctoral Science Foundation 2024M764303Nantong University Open Access Fund for Large-Scale Instruments and Equipment KFJN2535National Natural Science Foundation of China 82473840
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a severe autoimmune disease characterized by dysregulated functions of multiple immune cells such as phagocytes, lymphocytes, and dendritic cells. Bruton's tyrosine kinase (BTK) and FMS-like tyrosine kinase 3 (FLT3) play critical roles in RA pathogenesis, regulating B-cell survival, myeloid cell differentiation, and dendritic cell activation. Starting from the lead compound CC-292, a series of novel 5-fluoro-aminopyrimidine derivatives were designed and synthesized as dual BTK/FLT3 inhibitors for potential RA therapy. Our in vitro screening revealed that compounds 7a, 7b, and 7c are potent dual inhibitors, demonstrating potent activity with IC

Indexed as

Agammaglobulinaemia Tyrosine KinaseArthritis, RheumatoidDrug Discoveryfms-Like Tyrosine Kinase 3Protein Kinase InhibitorsPyrimidinesAnimalsArthritis, ExperimentalHumansMiceMicrosomes, LiverStructure-Activity RelationshipAgammaglobulinaemia Tyrosine KinaseBTK protein, humanfms-Like Tyrosine Kinase 3Protein Kinase InhibitorsPyrimidines5-Fluoro-aminopyrimidineBruton’s tyrosine kinase (BTK)Dual inhibitorFMS-like tyrosine kinase 3 (FLT3)Rheumatoid arthritis

Identifiers

PMID41706296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.